Project Grant R01HL174996
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$699K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The University of California, Davis received a 5-year, $1,738,092 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on heart failure with preserved ejection fraction (HFpEF). The funding will enable the development of computational models and conduct experimental studies to identify key molecular and cellular changes in HFpEF, explore the impact of phenotypic heterogeneity on disease...
This $817,208 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the genetic basis and underlying biological mechanisms of heart failure. The primary awardee, The Broad Institute, Inc., will leverage high-throughput cell imaging and transcriptional profiling assays to systematically analyze the impact of genes associated with heart failure identified through genome-wide...
This Project Grant award of $1,309,340.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of coronary microvascular dysfunction in the development of heart failure with preserved ejection fraction (HFpEF). The key objectives are to study how microRNA-21 (miR-21) regulates coronary microvascular function, cardiac function, and remodeling in a mouse model of HFpEF induced by a...
The federal Project Grant award R01HL174472, totaling $1,535,625.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research on ZFP36, an RNA-binding protein that regulates DNA repair and cell proliferation in pulmonary arterial hypertension (PAH). The research conducted at the University of California, Los Angeles (UCLA) aims to decode the causes of gene expression deregulation in PAH and...
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $671,254 Project Grant to Northwestern University to elucidate key metabolic pathways linked to left atrial (LA) dysfunction as a shared upstream phenotype of atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). The grant aims to leverage multimodal measures of LA function at rest and after hemodynamic provocation in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $500,089.80 award will support a 3-year research project to investigate the role of inflammatory macrophages in mediating cardiac remodeling and diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF). The University of Pittsburgh, a leading research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will provide $601,563 to the University of Texas Health Science Center at Houston (UTHealth) from September 1, 2024 through August 31, 2027. The grant aims to determine the pathogenic roles and molecular targets of two histone demethylases, KDM5A and KDM5B, in the development and progression of heart failure, particularly in the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The funding will support research to characterize the role of the RPS6KB1 protein as an integrative player in the pathological cardiac remodeling that occurs in hypertensive heart disease and heart failure. Key components of the research include further studying the mechanisms of RPS6KB1...
This Project Grant award of $777,674.00, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), supports a research project to evaluate the effectiveness of guideline-directed medical therapies (GDMT) for heart failure with mid-range ejection fraction (HFmrEF). The primary objectives are to build a large echocardiography registry, test statistical assumptions for applying causal inference methods, and then use the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $742,320 to the University of California, Los Angeles (UCLA) for research on adenine metabolism and its role in cardiac repair after myocardial infarction. The goal is to understand the mechanisms of extracellular nucleotide metabolism, adenine generation, and downstream effects on NAD and pyrimidine biosynthesis, with the aim of...